| __timestamp | Halozyme Therapeutics, Inc. | Lantheus Holdings, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22732000 | 176081000 |
| Thursday, January 1, 2015 | 29245000 | 157939000 |
| Friday, January 1, 2016 | 33206000 | 164073000 |
| Sunday, January 1, 2017 | 31152000 | 169243000 |
| Monday, January 1, 2018 | 10136000 | 168489000 |
| Tuesday, January 1, 2019 | 45546000 | 172526000 |
| Wednesday, January 1, 2020 | 43367000 | 200649000 |
| Friday, January 1, 2021 | 81413000 | 237513000 |
| Saturday, January 1, 2022 | 139304000 | 353358000 |
| Sunday, January 1, 2023 | 192361000 | 586886000 |
| Monday, January 1, 2024 | 159417000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology and pharmaceuticals, cost efficiency is paramount. Over the past decade, Halozyme Therapeutics, Inc. and Lantheus Holdings, Inc. have demonstrated contrasting trends in their cost of revenue. From 2014 to 2023, Halozyme's cost of revenue surged by approximately 747%, while Lantheus saw a 233% increase. Notably, in 2023, Lantheus's cost of revenue was nearly three times that of Halozyme, highlighting a significant disparity in operational efficiency.
This analysis underscores the importance of strategic cost management in sustaining competitive advantage in the biotech sector.
Cost of Revenue Trends: Amgen Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Halozyme Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue Trends: Incyte Corporation vs Lantheus Holdings, Inc.
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs Halozyme Therapeutics, Inc.
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Lantheus Holdings, Inc.
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Veracyte, Inc.'s Expenses
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and HUTCHMED (China) Limited
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Agios Pharmaceuticals, Inc.'s Expenses
Lantheus Holdings, Inc. vs Perrigo Company plc: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Lantheus Holdings, Inc. and Supernus Pharmaceuticals, Inc.'s Expenses